Hapvida Participações e Investimentos Past Earnings Performance
Past criteria checks 0/6
Hapvida Participações e Investimentos's earnings have been declining at an average annual rate of -60.9%, while the Healthcare industry saw earnings growing at 11.6% annually. Revenues have been growing at an average rate of 38.2% per year.
Key information
-60.9%
Earnings growth rate
-58.9%
EPS growth rate
| Healthcare Industry Growth | 36.3% |
| Revenue growth rate | 38.2% |
| Return on equity | -0.6% |
| Net Margin | -1.1% |
| Next Earnings Update | 08 Aug 2024 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses Breakdown
How Hapvida Participações e Investimentos makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 27,649 | -314 | 6,123 | 0 |
| 31 Dec 23 | 27,383 | -740 | 6,042 | 0 |
| 30 Sep 23 | 26,950 | -1,027 | 6,233 | 0 |
| 30 Jun 23 | 26,390 | -785 | 6,430 | 0 |
| 31 Mar 23 | 25,633 | -936 | 6,552 | 0 |
| 31 Dec 22 | 23,749 | -776 | 6,078 | 0 |
| 30 Sep 22 | 19,845 | -261 | 5,177 | 0 |
| 30 Jun 22 | 16,083 | -252 | 4,049 | 0 |
| 31 Mar 22 | 12,402 | 166 | 3,079 | 0 |
| 31 Dec 21 | 9,883 | 498 | 2,554 | 0 |
| 30 Sep 21 | 9,558 | 389 | 2,451 | 0 |
| 30 Jun 21 | 9,125 | 595 | 2,307 | 0 |
| 31 Mar 21 | 8,799 | 769 | 2,163 | 0 |
| 31 Dec 20 | 8,555 | 783 | 2,071 | 0 |
| 30 Sep 20 | 8,067 | 901 | 1,769 | 0 |
| 30 Jun 20 | 7,256 | 865 | 1,590 | 0 |
| 31 Mar 20 | 6,456 | 809 | 1,329 | 0 |
| 31 Dec 19 | 5,634 | 850 | 1,118 | 0 |
| 30 Sep 19 | 5,060 | 875 | 982 | 0 |
| 30 Jun 19 | 4,908 | 852 | 898 | 0 |
| 31 Mar 19 | 4,411 | 714 | 852 | 0 |
| 31 Dec 18 | 4,576 | 787 | 951 | 0 |
| 30 Sep 18 | 4,408 | 1,201 | 835 | 0 |
| 31 Mar 18 | 4,383 | 768 | 796 | 0 |
| 31 Dec 17 | 3,848 | 649 | 805 | 0 |
| 31 Dec 16 | 3,036 | 457 | 680 | 0 |
| 31 Dec 15 | 2,459 | 301 | 617 | 0 |
| 31 Dec 14 | 1,964 | 270 | 437 | 0 |
Quality Earnings: HAPV3 is currently unprofitable.
Growing Profit Margin: HAPV3 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HAPV3 is unprofitable, and losses have increased over the past 5 years at a rate of 60.9% per year.
Accelerating Growth: Unable to compare HAPV3's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HAPV3 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (29.3%).
Return on Equity
High ROE: HAPV3 has a negative Return on Equity (-0.64%), as it is currently unprofitable.